Patient groups | |||
---|---|---|---|
CMVR | HIV+ | Controls | |
Demographics: | |||
Number | 11 | 16 | 29 |
Age | 42.7 (5.5) | 41.1 (4.5) | 42.9 (8.3) |
VA/logMAR | 0.09 (0.22) | 0.01 (0.07) | −0.02 (0.1) |
Achromatic: | |||
0.33 cpd | 1.43 (0.23) | 1.58 (0.21) | 1.53 (0.13) |
0.66 cpd | 1.75 (0.28) | 1.91 (0.20) | 1.87 (0.10) |
2.2 cpd | 2.12 (0.53)* | 2.43 (0.11) | 2.41 (0.19) |
3.3 cpd | 1.99 (0.58)† | 2.43 (0.15) | 2.38 (0.15) |
10 cpd | 1.43 (0.62)** | 1.91 (0.28) | 1.82 (0.24) |
17 cpd | 1.06 (0.53) | 1.37 (0.37) | 1.30 (0.28) |
Chromatic: | |||
RGDT | 0.73 (0.49)** | 0.42 (0.19) | 0.42 (0.16) |
TDT | 0.90 (0.45)‡ | 0.42 (0.16) | 0.40 (0.15) |
ACS was reduced significantly in patient with CMVR, at 2.2 (*p<0.05), 3.3 (†p<0.005), and 10 cpd (**p<0.01) compared with controls and patients with HIV infection. Chromatic discrimination threshold was reduced on the red-green (**p<0.01) and the tritan axes (‡p<0.0001).